No Data
No Data
No Data
No Data
No Data
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Yahoo FinanceJan 15 03:04
PharmaTher Expects FDA to Decide on Ketamine Approval by April 29
Seeking AlphaJan 11 00:56
PharmaTher Provides Update for Expected FDA Approval of Ketamine
TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a specialty pharmaceutical company, is pleased to provide an update for the Company's lead
GlobeNewswireJan 10 20:30
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedeli
BenzingaOct 2, 2023 21:46
PharmaTher Is 'One Step Closer To Being A Ketamine Leader' Due To FDA Acceptance
The Food and Durg Administration (FDA) has accepted specialty biopharma company PharmaTher Holdings' (OTCQB:PHRRF) new drug application for a racemic ketamine product. What Happened: The so-called go
BenzingaSep 28, 2023 02:38
PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX (Ketamine)
FDA assigns GDUFA goal date of April 29, 2024 Milestone builds upon PharmaTher's commitment toward unlocking the potential of ketamine for unmet medical needs TORONTO, Sept. 27, 2023 (GLOBE NEWSWIRE) -- PharmaTher
GlobeNewswireSep 27, 2023 19:30
No Data
No Data